MiMedx Group Stock Forecast, Price & News

MiMedx Group (NASDAQ:MDXG) Frequently Asked Questions

Is MiMedx Group a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MiMedx Group stock.
View analyst ratings for MiMedx Group or view top-rated stocks.

How has MiMedx Group's stock been impacted by Coronavirus?

MiMedx Group's stock was trading at $5.45 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MDXG stock has increased by 25.0% and is now trading at $6.81.
View which stocks have been most impacted by COVID-19.

When is MiMedx Group's next earnings date?

MiMedx Group is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022.
View our earnings forecast for MiMedx Group.

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) announced its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.04. MiMedx Group had a negative trailing twelve-month return on equity of 1,262.51% and a negative net margin of 12.34%. During the same quarter in the previous year, the firm earned ($0.48) EPS.
View MiMedx Group's earnings history.

What guidance has MiMedx Group issued on next quarter's earnings?

MiMedx Group updated its FY 2021 earnings guidance on Wednesday, November, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $245 million-$255 million, compared to the consensus revenue estimate of $250.81 million.

What price target have analysts set for MDXG?

2 equities research analysts have issued 1 year price objectives for MiMedx Group's stock. Their forecasts range from $8.50 to $23.00. On average, they expect MiMedx Group's stock price to reach $15.75 in the next year. This suggests a possible upside of 131.3% from the stock's current price.
View analysts' price targets for MiMedx Group or view top-rated stocks among Wall Street analysts.

Who are MiMedx Group's key executives?

MiMedx Group's management team includes the following people:

• Timothy R. Wright, Chief Executive Officer & Director
• Scott M. Turner, Senior Vice President-Operations & Procurement
• Peter M. Carlson, Chief Financial Officer
• David H. Mason, Chief Medical Officer
• Robert Benjamin Stein, Executive Vice President-Research & Development

Who are some of MiMedx Group's key competitors?

Some companies that are related to MiMedx Group include Nevro (NVRO), AtriCure (ATRC), iRhythm Technologies (IRTC), Haemonetics (HAE), NuVasive (NUVA), Axonics (AXNX), Glaukos (GKOS), Paragon 28 (FNA), Silk Road Medical (SILK), Inovio Pharmaceuticals (INO), Procept BioRobotics (PRCT), Atrion (ATRI), Cerus (CERS), OrthoPediatrics (KIDS) and Pulmonx (LUNG).
View all of MDXG's competitors.

What is MiMedx Group's stock symbol?

MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."

Who are MiMedx Group's major shareholders?

MiMedx Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.60%), Geode Capital Management LLC (1.49%), Pura Vida Investments LLC (1.14%), Polar Asset Management Partners Inc. (0.71%), Parsons Capital Management Inc. RI (0.66%) and Bank of New York Mellon Corp (0.39%).
View institutional ownership trends for MiMedx Group.

Which institutional investors are selling MiMedx Group stock?

MDXG stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Beck Mack & Oliver LLC, NovaPoint Capital LLC, Citigroup Inc., Geode Capital Management LLC, Morgan Stanley, Parsons Capital Management Inc. RI, and California State Teachers Retirement System.
View insider buying and selling activity for MiMedx Group or view top insider-selling stocks.

Which institutional investors are buying MiMedx Group stock?

MDXG stock was purchased by a variety of institutional investors in the last quarter, including Polar Asset Management Partners Inc., BlackRock Inc., Royal Bank of Canada, Pura Vida Investments LLC, Fisher Asset Management LLC, Millennium Management LLC, Boyd Watterson Asset Management LLC OH, and Next Capital Management LLC.
View insider buying and selling activity for MiMedx Group or or view top insider-buying stocks.

How do I buy shares of MiMedx Group?

Shares of MDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MiMedx Group's stock price today?

One share of MDXG stock can currently be purchased for approximately $6.81.

How much money does MiMedx Group make?

MiMedx Group has a market capitalization of $763.67 million and generates $248.23 million in revenue each year. The company earns $-49.28 million in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does MiMedx Group have?

MiMedx Group employs 735 workers across the globe.

What is MiMedx Group's official website?

The official website for MiMedx Group is www.mimedx.com.

Where are MiMedx Group's headquarters?

MiMedx Group is headquartered at 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062.

How can I contact MiMedx Group?

MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The company can be reached via phone at (770) 651-9100, via email at [email protected], or via fax at 678-384-6741.